ライフサイエンスコーパス: autoimmune disorder

1 nd function, leading to a fatal, early-onset autoimmune disorder.

2 n a severe, multi-organ, lymphoproliferative autoimmune disorder.

3 matosus (SLE) is a devastating multisystemic autoimmune disorder.

4 mechanisms responsible for this prototypical autoimmune disorder.

5 myasthenia gravis (MG) is a relatively rare autoimmune disorder.

6 ere were 20 patients (50%) with some form of autoimmune disorder.

7 and factor (VWF) antibody associated with an autoimmune disorder.

8 inhibition of PHD2 in vivo leads to systemic autoimmune disorder.

9 OM5 enhancers in asthma, eczema, thyroid and autoimmune disorders.

10 rgeted for the treatment of Th17 cell-driven autoimmune disorders.

11 However, overproduction is associated with autoimmune disorders.

12 he treatment of multiple sclerosis and other autoimmune disorders.

13 cture in major infectious, inflammatory, and autoimmune disorders.

14 nisms present in several diseases, including autoimmune disorders.

15 necroptosis may underlie human fibrotic and autoimmune disorders.

16 venue for the treatment of type I IFN-linked autoimmune disorders.

17 le forms (sTyro3, sAxl, sMer) are related to autoimmune disorders.

18 FNalpha expression that occur during certain autoimmune disorders.

19 cal role of these cells in the regulation of autoimmune disorders.

20 l disease, and exert pathological effects in autoimmune disorders.

21 improve the treatment of MS, or indeed other autoimmune disorders.

22 2 C1858T) has been linked to a wide range of autoimmune disorders.

23 lls may be a promising strategy for treating autoimmune disorders.

24 ling, myocardial injury, atherosclerosis and autoimmune disorders.

25 may present a therapeutic strategy for these autoimmune disorders.

26 od-onset interferonopathy and adult systemic autoimmune disorders.

27 l, and/or function in T1D and possibly other autoimmune disorders.

28 function and has been implicated in several autoimmune disorders.

29 peutic potential for Treg-based therapies of autoimmune disorders.

30 s potential in a variety of inflammatory and autoimmune disorders.

31 erapies for cancer, infectious diseases, and autoimmune disorders.

32 een linked to immune deficiencies as well as autoimmune disorders.

33 at could be employed to inhibit the ROCKs in autoimmune disorders.

34 central in the pathogenesis of inflammatory autoimmune disorders.

35 vantage than men, yet they are more prone to autoimmune disorders.

36 valuated for the therapy of inflammatory and autoimmune disorders.

37 Rac1-targeting chemotherapeutic agent(s) for autoimmune disorders.

38 lso used to treat several systemic and local autoimmune disorders.

39 ells and may thus contribute to the onset of autoimmune disorders.

40 xacerbate symptoms associated with other CNS autoimmune disorders.

41 CD4(+) T-cells widely implicated in various autoimmune disorders.

42 pe I interferons (IFNs) and in patients with autoimmune disorders.

43 e have been identified as common to multiple autoimmune disorders.

44 ere complication of lupus and other systemic autoimmune disorders.

45 rs for applications as diverse as cancer and autoimmune disorders.

46 ional risk factors, such as individuals with autoimmune disorders.

47 e abnormalities that could increase risk for autoimmune disorders.

48 etic susceptibility to CVID may overlap with autoimmune disorders.

49 for immunomodulatory effects on allergic and autoimmune disorders.

50 y while uncontrolled responses can result in autoimmune disorders.

51 utic candidates for the treatment of various autoimmune disorders.

52 spected to underlie the rising prevalence of autoimmune disorders.

53 cts of sunlight UV exposure in patients with autoimmune disorders.

54 polymorphism (SNP) associated with multiple autoimmune disorders.

55 pathogenesis of multiple sclerosis and other autoimmune disorders.

56 ascular events, and diverse inflammatory and autoimmune disorders.

57 us pathogens and, at the same time, to avoid autoimmune disorders.

58 revention and treatment of CNS-demyelinating autoimmune disorders.

59 jection and type 1 diabetes as well as other autoimmune disorders.

60 auma exposure and PTSD may increase risk for autoimmune disorders.

61 HLA instability mediates the development of autoimmune disorders.

62 g pathogenic Th17 cells for the treatment of autoimmune disorders.

63 the treatment of allergic, inflammatory and autoimmune disorders.

64 play a major role in antiviral immunity and autoimmune disorders.

65 se overexpression is associated with several autoimmune disorders.

66 mulatory RNA, with implications for specific autoimmune disorders.

67 nked to the pathogenesis of inflammatory and autoimmune disorders.

68 elopment of novel therapeutic strategies for autoimmune disorders.

69 toimmune (type 1) diabetes and certain other autoimmune disorders.

70 It promotes the expansion of Th17 cells in autoimmune disorders.

71 ecessive genetic phenotypes in a spectrum of autoimmune disorders.

72 lation of treatment approaches from, primary autoimmune disorders.

73 the pathogenesis of chronic inflammatory and autoimmune disorders.

74 Goutieres Syndrome (AGS) or other lupus-like autoimmune disorders.

75 is strongly associated with T cell-mediated autoimmune disorders.

76 be beneficial in patients with MS and other autoimmune disorders.

77 is a major determinant of susceptibility to autoimmune disorders.

78 n of tolerogenic circuits and development of autoimmune disorders.

79 ng innate immunosuppression for treatment of autoimmune disorders.

80 om effects on cell growth and development to autoimmune disorders.

81 antagonists for the treatment of cancer and autoimmune disorders.

82 rapeutic options for modulating inflammatory/autoimmune disorders.

83 of developing IBD, but promotes the onset of autoimmune disorders.

84 ondition characterized by high prevalence of autoimmune disorders.

85 sponses driving multiple sclerosis and other autoimmune disorders.

86 demyelinating diseases and potentially other autoimmune disorders.

87 e thought to contribute to the initiation of autoimmune disorders.

88 at blocking this pathway exacerbates certain autoimmune disorders.

89 ), 2) psychiatric diagnosis, and 3) specific autoimmune disorders.

90 ent individuals and implications in treating autoimmune disorders.

91 nti-IDs) is considered a functional event in autoimmune disorders.

92 diabetes, cancer, neurological diseases, and autoimmune disorders.

93 MS and likely other T cell-dependent chronic autoimmune disorders.

94 e used to manage a wide range of cancers and autoimmune disorders.

95 not much is known about the role of SphK2 in autoimmune disorders.

96 e for the chronic treatment of B cell-driven autoimmune disorders.

97 Autoimmune disorders (24 patients [17%]) and CU (17 pati

98 years; median AMA titer 1:160; extrahepatic autoimmune disorders 46%; normal serum alkaline phosphat

99 ), inflammatory arthritis (27 358), systemic autoimmune disorders (7472), and systemic vasculitis (62

100 gents in cancer, ageing-related diseases and autoimmune disorders(8), and so a general strategy to se

101 mutation carriers have an increased risk of autoimmune disorders, accompanied by elevated levels of

102 he possibility that this disorder or similar autoimmune disorders affecting synaptic proteins, which

103 e trained immunity, such as inflammatory and autoimmune disorders, allergies and cardiovascular disea

104 ive risk (ARR) for diagnosis with any of the autoimmune disorders alone or in combination compared wi

105 However, little is known about the risk for autoimmune disorders among individuals with PTSD.

106 presses immune responses in animal models of autoimmune disorders and allograft rejection.

107 re implicated in cancer and inflammatory and autoimmune disorders and are targets of numerous antagon

108 merged as a promising therapeutic target for autoimmune disorders and cancer.

109 , and potent inhibitors for the treatment of autoimmune disorders and cancer.

110 eases, including neurodegenerative diseases, autoimmune disorders and cancer.

111 eover, B cell misregulation is implicated in autoimmune disorders and cancers such as multiple sclero

112 Both are widely used to treat autoimmune disorders and certain cancers.

113 omplicated causes, such as cancer, diabetes, autoimmune disorders and degenerative diseases.

114 omosomal errors, anatomical uterine defects, autoimmune disorders and endometrial dysfunction.

115 mal models, Tregs have been shown to prevent autoimmune disorders and establish transplantation toler

116 as found in the bone marrow of patients with autoimmune disorders and in NPM1-mutated acute myelogeno

117 c pathways has led to new drugs for cancers, autoimmune disorders and infectious diseases.

118 ses, hepatitis, neurodegenerative disorders, autoimmune disorders and inflammatory skin diseases.

119 n occurs with GABAergic and other coexisting autoimmune disorders and is potentially treatable.

120 B cells contribute to multiple aspects of autoimmune disorders and may play a role in triggering d

121 In addition, the GBM is affected by acquired autoimmune disorders and metabolic diseases such as diab

122 ing (RBR) E3 ligases have been implicated in autoimmune disorders and neurodegenerative diseases.

123 enous retroviruses are associated with human autoimmune disorders and neurodegenerative diseases.

124 In addition, PVOD has also been linked to autoimmune disorders and occupational solvent exposure.

125 The initial trigger for both systemic autoimmune disorders and organ-specific autoimmune disor

126 nal disease, pulmonary alveolar proteinosis, autoimmune disorders and osteoporosis, are limited.

127 cognized, role for AS in the pathogenesis of autoimmune disorders and particularly for T1D.

128 ected therapies do not need to be limited to autoimmune disorders and that topical tofacitinib applic

129 REX1) is a known DNA exonuclease involved in autoimmune disorders and the antiviral response.

130 ations of psychosis with a family history of autoimmune disorders and vice versa.

131 lved in dysregulation of pathways leading to autoimmune disorders and/or immune deficiencies.

132 CD46 deficiency causes an autoimmune disorder, and this protein is also involved i

133 l and is crucially involved in inflammation, autoimmune disorders, and cancer progression.

134 emerging functions in immune regulation and autoimmune disorders, and discuss the identification and

135 re effective in animal models of cancers and autoimmune disorders, and early-phase clinical trials ar

136 iated with cardiovascular, neurological, and autoimmune disorders, and in some cases directly impact

137 ples from patients with varied infectious or autoimmune disorders, and in the case of Sjogren's syndr

138 y conditions such as traumatic brain injury, autoimmune disorders, and infections to neuropsychiatric

139 CDDO-DFPA in the treatment and prevention of autoimmune disorders, and its capacity to induce toleran

140 bacterial infections, neurodegenerative and autoimmune disorders, and more.

141 ortant target with reported roles in cancer, autoimmune disorders, and neurodegenerative diseases.

142 stance and type 2 diabetes, inflammatory and autoimmune disorders, and neurological disorders.

143 Autoimmune disorders are also overrepresented in both AL

144 Rheumatoid arthritis and other autoimmune disorders are associated with altered activit

145 Some autoimmune disorders are monogenetic diseases; however,

146 Infections and autoimmune disorders are more frequent in Down syndrome,

147 portions of patients with NCWS or CD develop autoimmune disorders, are ANA positive, and showed DQ2/D

148 CR, and TLR signals in WAS, and likely other autoimmune disorders, are sufficient to alter B cell tol

149 To make genetic comparisons across autoimmune disorders as informative as possible, a dense

150 ders such as obesity, diabetes mellitus, and autoimmune disorders as well as neuropsychiatric disorde

151 ious immune system genes to common polygenic autoimmune disorders, as well as the pathophysiologic pa

152 Systemic lupus erythematosus is an autoimmune disorder associated with the accumulation of

153 being repositioned to treat inflammatory and autoimmune disorders at lower doses by targeting Tregs.

154 ently published study suggests that NS is an autoimmune disorder based on findings of cross-reacting

155 s with multiple myeloma and B cell-dependent autoimmune disorders but exert toxicity from inhibition

156 bodies for the treatment of malignancies and autoimmune disorders but whose structure and function ar

157 as a potential treatment for alloimmune and autoimmune disorders, but it is unknown whether disturba

158 an established therapeutic target in myriad autoimmune disorders, but no TLR7 antagonist is availabl

159 s pathogens contribute to the development of autoimmune disorders, but the mechanisms connecting thes

160 Regulatory T (Treg) cells prevent autoimmune disorders by suppressing excessive lymphocyte

161 ly unclear if T reg cell deficiency-mediated autoimmune disorders can be treated by targeting the ent

162 ectious diseases, including malignancies and autoimmune disorders, can also be involved.

163 d in many pathological conditions, including autoimmune disorders, cancer, and cardiovascular and all

164 is associated with mortality during sepsis, autoimmune disorders, cancer, and diabetes.

165 spectrum of diseases, including infections, autoimmune disorders, cancers, and pregnancy disorders,

166 like cancer, neurodegenerative diseases, or autoimmune disorders, caspases have been intensively inv

167 A syndrome is a recently described Mendelian autoimmune disorder caused by missense mutations in the

168 evident in the spectrum of inflammatory and autoimmune disorders caused by defects in PS receptors a

169 he knockout of KIF21B, a kinesin-4 linked to autoimmune disorders, causes microtubule overgrowth and

170 Systemic sclerosis (SSc) is a rare autoimmune disorder characterised by skin fibrosis that

171 Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by a breakdown of self

172 Neuromyelitis optica is a rare neurological autoimmune disorder characterized by a poor prognosis.

173 didiasis ectodermal dystrophy (APECED) is an autoimmune disorder characterized by chronic mucocutaneo

174 Systemic sclerosis (SSc) is an autoimmune disorder characterized by fibrosis of the ski

175 IgG4-RD is a multiorgan autoimmune disorder characterized by fibrous inflammatio

176 ntiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent thrombosi

177 Rheumatoid arthritis is an autoimmune disorder characterized by T cell dysregulatio

178 Evans syndrome (ES) is a rare severe autoimmune disorder characterized by the combination of

179 Sarcoidosis is a presumptive autoimmune disorder characterized by the presence of non

180 ions in host defense and in the pathology of autoimmune disorders, chronic inflammatory diseases, and

181 lls; antibodies, autoantibodies and comorbid autoimmune disorders; complement; oxidative stress; imag

182 hidia 3 (MORC3) is a human protein linked to autoimmune disorders, Down syndrome, and cancer.

183 s among populations is well-characterized in autoimmune disorders (e.g., rheumatoid arthritis), but t

184 elicobacter pylori, pneumonia) diseases, and autoimmune disorders (e.g., systemic lupus erythematosus

185 sk for autoimmune endocrinopathies and other autoimmune disorders, encode unstable proteins, whereas

186 ten arises in the presence of complications (autoimmune disorders, fractures, and finally, malignancy

187 bodies targeting host antigens contribute to autoimmune disorders, frequently occur during and after

188 ent conducted with MSCs from a donor with an autoimmune disorder had no positive effects on transplan

189 ly understood, but the occurrence of several autoimmune disorders has been found to vary along a Nort

190 rculating self-reactive IgE in patients with autoimmune disorders has been long known but, at the sam

191 isease-associated signals, predominantly for autoimmune disorders, highlighting intermediate phenotyp

192 ding onset of OMG and GMG, presence of other autoimmune disorders, history of smoking, presence of th

193 esent an alternative approach for therapy of autoimmune disorders; however, dietary antioxidants are

194 e strongly associated with susceptibility to autoimmune disorders; however, it is not clear how genet

195 lleagues characterized a seemingly monogenic autoimmune disorder in a family that was linked to homoz

196 =2) each occurring in more than one patient (autoimmune disorder in two patients at 10 mg/kg and one

197 y expressed antigens can blunt various liver autoimmune disorders in a non-disease-specific manner wi

198 The prevalence of autoimmune disorders in affluent countries has reached e

199 These irAEs can be compared with known autoimmune disorders in similar tissues, with important

200 erapeutic target for CD or potentially other autoimmune disorders in which NKG2D has been implicated.

201 A but will also likely be relevant for other autoimmune disorders in which pathobiology, ectopic MHC

202 bition of IRAK4 as a therapeutic strategy in autoimmune disorders, in a genetically defined populatio

203 f the major genetic risk factors for several autoimmune disorders including type 1 diabetes (T1D) in

204 IFIH1 has been linked to a number of autoimmune disorders, including Aicardi-Goutieres syndro

205 ia (CSU) are widely held to often have other autoimmune disorders, including autoimmune thyroid disea

206 s IL21 and IL15 contribute to development of autoimmune disorders, including celiac disease.

207 n the putative treatment of inflammatory and autoimmune disorders, including experimental autoimmune

208 e nature of microbial involvement in complex autoimmune disorders, including human autoimmune polygla

209 as an inflammation mediator in a variety of autoimmune disorders, including inflammatory bowel disea

210 in diseased tissues of patients with various autoimmune disorders, including multiple sclerosis (MS).

211 ributing factors to the pathogenesis of many autoimmune disorders, including multiple sclerosis.

212 JAK inhibitors hold promise for treatment of autoimmune disorders, including rheumatoid arthritis, in

213 ession will provide new treatment options in autoimmune disorders, including SLE.

214 ry sexual trauma exposure increased risk for autoimmune disorders, including thyroiditis, inflammator

215 Treg insufficiency can lead to autoimmune disorders, including type 1 diabetes (T1D).

216 been linked with the development of various autoimmune disorders, including type 1 diabetes.

217 ardiometabolic disorders, allergic diseases, autoimmune disorders, infections, and cancers.

218 The relationship between allergy and autoimmune disorders is complex and poorly understood.

219 Thus, the scope of antigen spreading in autoimmune disorders is larger than previously anticipat

220 limumab therapy in patients with preexisting autoimmune disorders is not known.

221 hogenesis of type 1 diabetes (T1D), a common autoimmune disorder, is not completely understood.

222 r, their use is generally discouraged in the autoimmune disorder known as immune thrombocytopenia (IT

223 matosus (SLE) is a chronic, life-threatening autoimmune disorder, leading to multiple organ pathologi

224 blockade is a successful treatment for human autoimmune disorders like rheumatoid arthritis and infla

225 ng a previously reported type 1 diabetes and autoimmune disorder locus.

226 ht trigger or exacerbate the symptoms of the autoimmune disorder lupus erythematosus is not known but

227 e was performed on the use of AIT in asthma, autoimmune disorders, malignant neoplasias, cardiovascul

228 occurred in nine (17%) of 53 patients, with autoimmune disorder (n=3), increased blood creatine phos

229 h have been linked to human diseases such as autoimmune disorders, neurodegenerative diseases and can

230 elated with a variety of pathologies such as autoimmune disorders, neurodegenerative diseases, and ca

231 s experienced recurrence of their underlying autoimmune disorders, none of the chimeric subjects have

232 Autoimmune disorders occur when the immune system abnorm

233 Myasthenia gravis (MG), an autoimmune disorder of neuromuscular transmission, is tr

234 pathogenesis of multiple sclerosis (MS), an autoimmune disorder of the CNS and thus analyzed the mic

235 Systemic sclerosis (SSc) is a polygenic, autoimmune disorder of unknown etiology, characterized b

236 Autoimmune disorders of the CNS have complex pathogenese

237 a spectrum disorders (NMOSD) constitute rare autoimmune disorders of the CNS that are primarily chara

238 ential therapeutic intervention for managing autoimmune disorders of the CNS.

239 patients treated at 10 mg/kg dose level, and autoimmune disorder (one [5%]), increased amylase (one [

240 complicated by infection, and less commonly, autoimmune disorders or malignancy.

241 essure fluctuations, use of cytotoxic drugs, autoimmune disorders, or eclampsia.

242 conditions, including inflammatory diseases, autoimmune disorders, pain, and cancer.

243 Individuals suffering from autoimmune disorders possess a hyperactive cellular phen

244 emic autoimmune disorders and organ-specific autoimmune disorders probably involves the recognition o

245 However, the direct role of hCMV in inducing autoimmune disorders remains unclear.

246 insulin deficiency, is considered a chronic autoimmune disorder resulting from the destruction of in

247 Rheumatoid arthritis is a chronic autoimmune disorder resulting in synovial inflammation.

248 uced T reg cell proliferation, and a rampant autoimmune disorder similar in severity to that triggere

249 f symptoms probably indicative of coexisting autoimmune disorders: six had encephalitis with seizures

250 rovide benefit to patients with inflammatory autoimmune disorders such as Crohn's disease, rheumatoid

251 iotypic Parkinson's disease (PD) and also to autoimmune disorders such as Crohn's disease.

252 Disease activity of autoimmune disorders such as multiple sclerosis and its

253 ll differentiation and have implications for autoimmune disorders such as multiple sclerosis.

254 salivary glands resulting from infection or autoimmune disorders such as Sjogren's syndrome.

255 Da RNA-binding protein and an autoantigen in autoimmune disorders such as systemic lupus erythematosu

256 RCA may be associated with collagen vascular/autoimmune disorders such as systemic lupus erythematosu

257 xp3(+) CD25(+) CD4(+) Treg cells and inhibit autoimmune disorders such as type 1 diabetes.

258 gested to play a role in the pathogenesis of autoimmune disorders such as type 1 diabetes.

259 rrant activity is also implicated in several autoimmune disorders, such as Sjogren syndrome.

260 , is also associated with haematological and autoimmune disorders, suggesting that it influences canc

261 nce in mouse models of T1D, as well as other autoimmune disorders, suggests that there are defects in

262 The etiology of the autoimmune disorder systemic lupus erythematosus (SLE) r

263 opathy that phenotypically overlaps with the autoimmune disorder systemic lupus erythematosus.

264 diagnoses included nutritional deficiencies, autoimmune disorders, systemic malignancies, and intracr

265 oid arthritis (RA) is a chronic inflammatory autoimmune disorder that affects joints of hands and fee

266 have been observed in multiple sclerosis, an autoimmune disorder that affects the CNS.

267 Rheumatoid arthritis is an autoimmune disorder that affects the joints and other or

268 Graves' disease is an autoimmune disorder that causes hyperthyroidism because

269 Rheumatoid arthritis (RA) is a chronic autoimmune disorder that causes joint inflammation and d

270 Type 1 diabetes is an autoimmune disorder that is characterized by a failure o

271 Primary acquired PRCA is an autoimmune disorder that is frequently antibody-mediated

272 Celiac disease is an autoimmune disorder that is induced by dietary gluten in

273 he developing evidence that narcolepsy is an autoimmune disorder that may be caused by a T cell-media

274 IPEX is a fatal X-linked autoimmune disorder that results from mutations in the c

275 Myasthenia gravis is an autoimmune disorder that selectively targets neuromuscul

276 ement functions occur in many infectious and autoimmune disorders that have been linked to schizophre

277 tivating mutations in STAT3 with early-onset autoimmune disorders that include diabetes of autoimmune

278 toreactive clones among CD21(low) B cells in autoimmune disorders, the dominant role of SYK in CD21(l

279 thase for the initiation of self-DNA-induced autoimmune disorders, thus providing important implicati

280 paB signaling is implicated in diseases from autoimmune disorders to cancer.

281 Celiac disease is an autoimmune disorder triggered by gluten in genetically p

282 d a serious treatment-related adverse event: autoimmune disorder (two [13%]), lower abdominal pain (o

283 s with known biological connections, such as autoimmune disorders (type 1 diabetes, rheumatoid arthri

284 unctions in patients with atopic conditions, autoimmune disorders, type 2 diabetes, chronic urticaria

285 multiple neuronal antigens implicated in CNS autoimmune disorders, using fixed and live cell-based as

286 ude of the PTSD-related increase in risk for autoimmune disorders was similar in women and men, and m

287 alarial drugs (AMDs) on clinical features of autoimmune disorders were discovered by chance during Wo

288 Other infectious or autoimmune disorders were excluded.

289 , FcRn can contribute to the pathogenesis of autoimmune disorders when an abnormal immune response ta

290 Multiple sclerosis (MS) is an autoimmune disorder where T cells attack neurons in the

291 eptor encephalitis is a severe but treatable autoimmune disorder which diagnosis depends on sensitive

292 the symptoms of mood disorders overlap with autoimmune disorders, which also have a higher prevalenc

293 ients with advanced melanoma and preexisting autoimmune disorders who received ipilimumab at 9 academ

294 c lupus erythematosus (SLE) is a multi-organ autoimmune disorder with a prominent genetic component.

295 tients with systemic lupus erythematosus, an autoimmune disorder with a strong female bias, and obser

296 in inflammatory aortic disease, a rare human autoimmune disorder with increased levels of IL-17A.

297 Antiphospholipid syndrome (APS) is an autoimmune disorder with increased risk for thrombosis a

298 trongly involved in several inflammatory and autoimmune disorders with both pro- and anti-inflammator

299 alpha blockade may have therapeutic value in autoimmune disorders with DN T cell expansion.

300 the pathogenesis of several T cell-mediated autoimmune disorders, with molecular mimicry a likely me